Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Masamune Mitsumoto"'
Autor:
T. Shimamoto, Hitoo Nakano, Masamune Mitsumoto, Toshiyuki Shigematsu, Toshiharu Kamura, Kunihiro Sakai, Tsunehisa Kaku, Toshiaki Saito
Publikováno v:
Acta Obstetricia et Gynecologica Scandinavica. 78:452-457
Background. Lymph node metastasis has been one of the strongest prognostic factors in patients with cervical cancer. In order to select patients with high risk for recurrence, a relationship between status of lymph node and other histopathological pa
Autor:
Toshiharu Kamura, Toshiyuki Shigematsu, Tsunehisa Kaku, Tomihiro Shimamoto, Toshiaki Saito, Kunihiro Sakai, Masamune Mitsumoto, Hitoo Nakano
Publikováno v:
Acta Obstetricia et Gynecologica Scandinavica. 78:452-457
Autor:
Masamune Mitsumoto, Kenji Uehira, Kunihiro Sakai, Toshiaki Saito, Tsunehisa Kaku, Toshiyuki Shigematu, Hiroaki Kobayashi, Toshiharu Kamura
Publikováno v:
THE JOURNAL OF JAPAN SOCIETY FOR LASER SURGERY AND MEDICINE. 14:193-196
Autor:
Kimitoshi Kohno, Masamune Mitsumoto, Shinji Ogawa, Hitoo Nakano, Michihiko Kuwano, Takanori Sonoda, Satoshi Amada, Hideaki Yahata, Toshiharu Kamura, Hiroaki Kobayashi
Publikováno v:
Cancer. 85(11)
BACKGROUND Nuclear expression of Y box-binding protein (YB-1), a member of the DNA binding protein family, has been reported to be much more highly concentrated in cisplatin-resistant cell lines than in their parental counterparts, suggesting an abil
Autor:
Hitoo Nakano, Masamune Mitsumoto, Kunihiro Sakai, Tsunehisa Kaku, Masazumi Tsuneyoshi, Hiroaki Kobayashi, Toshiharu Kamura
Publikováno v:
Oncology reports. 6(1)
Progression of malignant potential in ovarian cancer was investigated by comparing recurrent tumor with their primary tumor counterparts in terms of p53 and CD44 variant 6 (CD44v6) expression. Forty-three paired primary and recurrent tumors were immu
Autor:
Masamune Mitsumoto, Tsunehisa Kaku, Hitoo Nakano, Hiroaki Kobayashi, Toshiharu Kamura, Takanori Sonoda
Publikováno v:
Journal of cancer research and clinical oncology. 124(11)
To establish a more suitable model for reflecting biological aggressiveness in clinically recurrent cancers after chemotherapy, we made the in-vitro-established cisplatin-resistant cell lines, by exposing the parental tumor cell lines to cisplatin in